

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace, without prejudice, all prior versions and listings of claims in the application.

1. – 50. (Cancelled)

51. (Previously Presented) A method for obtaining a library of at least two inhibitory antibodies against Factor VIII with variable maximal inhibitory activity and with substantially the same affinity, said method comprising modifying the size of an inhibitory antibody against Factor VIII or a fragment thereof, wherein said inhibitory antibody or fragment thereof comprises an immunoglobulin light chain sequence represented by SEQ ID NO: 4 and an immunoglobulin heavy chain sequence represented by SEQ ID NO: 2, by modifying the glycosylation in the variable region of said inhibitory antibody by mutating the glycosylation site at positions Asn47 and/or Thr49 of SEQ ID NO: 2 or deglycosylating position Asn47 of SEQ ID NO: 2, and selecting at least one antibody or fragment for which affinity is not substantially affected.

52. – 57. (Cancelled)

58. (Previously Presented) An inhibitory antibody against Factor VIII or a fragment thereof comprising an immunoglobulin light chain sequence represented by SEQ ID NO: 4, and comprising an immunoglobulin heavy chain amino acid sequence represented by SEQ ID NO: 2, wherein the glycosylation site at positions Asn47 and/or Thr49 of SEQ ID NO: 2 is mutated, or wherein position Asn47 of SEQ ID NO: 2 is deglycosylated.

59. (Previously Presented) The antibody or fragment thereof according to claim 58 wherein said glycosylation site is mutated by changing Asn47 to Gln47, Asn47 to Glu47, Asn47 to Asp47 and/or by changing Thr49 to Ala49.

60. (Previously Presented) The antibody or fragment thereof according to claim 58 wherein said

glycosylation site is mutated by changing Asn47 to Gln47.

61. – 63. (Cancelled)

64. (Currently Amended) An inhibitory antibody against Factor VIII or a fragment thereof comprising an immunoglobulin variable light chain comprising the CDR1, CDR2, and CDR3 regions depicted in SEQ ID NO: 36, SEQ ID NO: 37, and SEQ ID NO: 38 respectively, and comprising an immunoglobulin variable heavy chain comprising the CDR1, CDR2, and CDR3 regions depicted in SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35, respectively, wherein the glycosylation site at positions 3 and/or 5 in the CDR1 region of the immunoglobulin variable heavy side-chain comprising the sequence of SEQ ID NO: 33 is mutated, or wherein Asn at position 3 in the CDR1 region of the variable heavy chain comprising the sequence of SEQ ID NO: 33 is deglycosylated.

65. (Currently Amended) The antibody or fragment thereof according to claim 64, wherein the mutation is the change of Asn into Gln, Glu or Asp at position 3 in the CDR1 region of the immunoglobulin variable heavy side-chain comprising the sequence of SEQ ID NO: 33 and/or wherein the mutation is the change of Thr into Ala at position 5 in the CDR1 region of the immunoglobulin variable heavy side-chain comprising the sequence of SEQ ID NO: 33.

66. (Previously Presented) An inhibitory antibody against Factor VIII or a fragment thereof comprising an immunoglobulin variable heavy chain comprising the CDR1, CDR2, and CDR3 regions comprising the sequence of SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35, respectively, wherein the glycosylation site at positions 3 and/or 5 of the CDR1 region comprising the sequence of SEQ ID NO: 33 is mutated, or wherein Asn at position 3 in the CDR1 region comprising the sequence of SEQ ID NO: 33 is deglycosylated, and wherein the antibody or fragment thereof is an scFv fragment represented by SEQ ID NO: 26.

67. (Previously Presented) The fragment according to claim 58, which is an scFv fragment

represented by SEQ ID NO: 26.

68. (Previously Presented) The fragment according to claim 64, which is an scFv fragment represented by SEQ ID NO: 26.

69. (Cancelled)

70. (Previously Presented) A pharmaceutical composition comprising the inhibitory antibody or fragment thereof according to claim 58.

71. (Previously Presented) A pharmaceutical composition comprising the inhibitory antibody or fragment thereof according to claim 64.

72. (Previously Presented) A pharmaceutical composition comprising the inhibitory antibody or fragment thereof according to claim 66.

73. (Previously Presented) An antibody or antigen binding fragment thereof which is a modified antibody or modified fragment of an inhibitory antibody against Factor VIII, wherein the unmodified inhibitory antibody comprises as CDR1, CDR2, and CDR3 regions of the immunoglobulin variable heavy chain an amino acid sequence represented by SEQ ID NOS: 33, 34, and, 35, respectively, and comprises as CDR1, CDR2, and CDR3 regions of the immunoglobulin variable light chain an amino acid sequence represented by SEQ ID NOS: 36, 37, and 38, respectively, and wherein the unmodified antibody or antigen binding fragment thereof is obtainable by expression in a human lymphoblastoid cell line, wherein the modification is a deglycosylation at position 3 in the CDR1 region of the immunoglobulin variable heavy chain comprising the sequence of SEQ ID NO: 33.

74. (Previously Presented) A method for obtaining a library of at least two inhibitory antibodies against Factor VIII with variable maximal inhibitory activity and with substantially the same

affinity, said method comprising modifying the size of an inhibitory antibody against Factor VIII or a fragment thereof, wherein said inhibitory antibody or fragment thereof comprises an immunoglobulin variable light chain comprising the CDR1, CDR2, and CDR3 regions depicted in SEQ ID NO: 36, SEQ ID NO: 37, and SEQ ID NO: 38, respectively, and an immunoglobulin variable heavy chain comprising the CDR1, CDR2, and CDR3 regions depicted in SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35, respectively, by modifying the glycosylation in the variable region of said inhibitory antibody by mutating the glycosylation site at positions 3 and/or 5 in the CDR1 region of the immunoglobulin variable heavy chain comprising the sequence of SEQ ID NO: 33 or deglycosylating Asn at position 3 in the CDR1 region of the immunoglobulin variable heavy chain comprising the sequence of SEQ ID NO: 33, and selecting at least one antibody or fragment for which affinity is not substantially affected.

75. (Currently Amended) A method for obtaining a library of at least two inhibitory antibodies against Factor VIII with variable maximal inhibitory activity and with substantially the same affinity, said method comprising modifying the size of an inhibitory antibody against Factor VIII or a fragment thereof, wherein said inhibitory antibody or fragment thereof comprises an immunoglobulin variable heavy chain comprising the CDR1, CDR2, and CDR3 regions depicted in SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35, respectively, wherein the antibody or fragment thereof is an scFv fragment represented by SEQ ID NO: 26, by modifying the glycosylation in the variable region of said inhibitory antibody by mutating the glycosylation site at positions 3 and/or 5 in the CDR1 region of the immunoglobulin variable heavy chain comprising the sequence of SEQ ID NO: 33 or deglycosylating Asn at position 3 in the CDR1 region of the immunoglobulin variable heavy chain comprising the sequence of SEQ ID NO: 33, and selecting at least one antibody or fragment for which affinity is not substantially affected.

76. (Previously Presented) A library of factor VIII inhibitory antibodies obtained by the method according to claim 51.

77. (Previously Presented) A library of factor VIII inhibitory antibodies obtained by the method

according to claim 74.

78. (Previously Presented) A library of factor VIII inhibitory antibodies obtained by the method according to claim 75.